This review highlights the optimal selection of anticoagulants in ACS, emphasizing the advantages of enoxaparin over UFH, the risks of switching agents, and specific recommendations for patients with renal impairment.
No takes yet. Share an insight, caveat, or question.
Enoxaparin may be preferred over UFH in ACS; leaves open optimal use with contemporary antiplatelet strategies.
Смирнова et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: